Skip to main content
. 2015 Jun 26;17(7):1007–1017. doi: 10.1093/europace/euv068

Table 1.

Atrial fibrillation registries and surveys

Registry or study Guidelines Patients with AF, n Country/region Data collection, year OAC use (%)
GARFIELD-AF13 Multiple 10 614 Global 2009–2011 ∼60
RE-LY AF33 Multiple 15 400 Global 2008–2011 30
GLORIA-AF34 Multiple ∼56 000 Global 2011 onwards Awaiting data
Euro Heart Survey on AF35 ACC/AHA/ESC 2001 and ACCP 2004 5333 Europe 2003–2004 64
AFNET36 ACC/AHA/ESC 2001 9582 Germany 2004–2006 71
ATRIUM37 ACC/AHA/ESC 2001 and ACCP 2008 3667 Germany 2009 83
Prospective non-interventional study38 Not specified 2753 Germany 2010 64–73a
ISAF39 Not specified 6036 Italy 2011 46
PREFER AF42 ESC 2010 7243 Europe 2012–2013 82
Retrospective, cohort study43 ACC/AHA/ESC 2006 and ACCP 2008 171 393 USA 2003–2007 43
ORBIT-AF44 ACC/AHA/ESC 2006 and ACCP 2008 10 098 USA 2010–2011 76
REACH45 Not specified ∼300 Asia (ex. Japan) 2006–2011 36
REACH45 Not specified ∼350 Japan 2006–2011 54
REACH45 Not specified ∼6000 Global (ex. Asia) 2006–2011 55

ACC, American College of Cardiology; ACCP, American College of Chest Physicians; AF, atrial fibrillation; AFNET, Central Registry of the German Competence NETwork on Atrial Fibrillation; AHA, American Heart Association; ATRIUM, Outpatient Registry Upon Morbidity of Atrial Fibrillation; CHADS2, Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mellitus, prior Stroke/transient ischaemic attack (doubled); ESC, European Society of Cardiology; GARFIELD-AF, Global Anticoagulant Registry in the FIELD; GLORIA-AF, Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation; ISAF, Italian Network of Atrial Fibrillation Management survey; OAC, oral anticoagulant; ORBIT-AF, Outcomes Registry for Better Informed Treatment of Atrial Fibrillation; PREFER AF, PREvention oF thromboembolic events—European Registry in Atrial Fibrillation; REACH, REduction of Atherothrombosis for Continued Health; RE-LY AF, Randomized Evaluation of Long-term anticoagulant TherapY.

aCHADS2 score ≥2 (includes low molecular weight heparin).